U.S. Surgeon General Urges Action to End Tobacco-Related Disease and Disparities

Nov.20.2024
U.S. Surgeon General Urges Action to End Tobacco-Related Disease and Disparities
The U.S. Surgeon General highlights persistent disparities in tobacco use and secondhand smoke exposure, urging stronger policies, equitable healthcare access, and targeted measures to reduce tobacco-related harm.

The U.S. Surgeon General has released a new report highlighting health disparities related to tobacco use, according to the U.S. Department of Health and Human Services on November 19.

 

The report emphasizes that despite substantial progress in reducing smoking rates and secondhand smoke exposure, these improvements have not been equally experienced across all population groups.

 

Since 1965, smoking rates in the United States have dropped by over 70%. However, disparities in tobacco use persist due to factors such as race and ethnicity, income, education, sexual orientation and gender identity, occupation, geography, behavioral health status, and other factors. 

 

Disparities persist in smoking prevalence and related health outcomes among specific groups, including American Indians, Alaska Natives, and individuals living in poverty.

 

The report highlights disparities in secondhand smoke exposure as well. Smoking and secondhand smoke still cause nearly 500,000 deaths in the United States each year, accounting for one-fifth of all deaths.

 

While death rates from secondhand smoke have fallen by over 50% since 2006, children, African Americans, low-income individuals, and adults with lower education levels remain disproportionately affected. These disparities have widened since 2000.

 

Smoking continues to be a leading cause of preventable disease and death in the U.S., with varying impacts. For instance, American Indians and Alaska Natives experience the highest rates of chronic obstructive pulmonary disease (COPD), while black males face the highest incidence and mortality rates from lung cancer.

 

The report identifies multiple factors driving tobacco-related disparities, including poverty, racism, discrimination, inadequate healthcare access, and targeted strategies by the tobacco industry. Additional barriers include limited access to quitting resources, insufficient tobacco prevention and control measures, and social and environmental influences.

 

To combat these disparities, the report calls for actions such as improving healthcare access, expanding smoke-free policies, reducing the appeal and addictiveness of tobacco products, and addressing social determinants of health. Equitable implementation of tobacco control strategies is essential to reducing smoking rates, exposure to secondhand smoke, and the overall burden of tobacco-related diseases.

 

"Tobacco use imposes a heavy toll on families across generations. Now is the time to accelerate our efforts to create a world in which zero lives are harmed by or lost to tobacco," said Surgeon General Dr. Vivek Murthy. 

 

"This report offers a vision for a tobacco-free future, focused on those who bear the greatest burden, and serves as a call to action for all people to play a role in realizing that vision," Dr. Vivek Murthy said.

 

"Tobacco use continues to decline. Americans increasingly understand tobacco products are dangerous and addictive and many are taking advantage of available tools to help them quit. That’s great news," said Xavier Becerra, HHS Secretary for Health. 

 

"Smoking is still the leading cause of preventable death in the United States. That’s unacceptable. We will keep working until tobacco is no longer a menace to individuals and families across the nation. We will continue our efforts to improve health equity and support communities that remain the most vulnerable," Becerra said.

 

BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
JTI Korea launched the Ploom AURA Teal Electric Pop limited edition in South Korea on September 1, 2026, marking the first dual-color design in the Ploom AURA range. The device combines a dark green body with teal accents and is accompanied by matching Front Panel, Back Cover and Pocket Bag accessories. The standalone device is priced at KRW 29,000, with three additional device-and-accessory bundles available. The release continues JTI Korea's use of limited colorways and interchangeable accessories to expand the Ploom AURA portfolio without introducing a new hardware platform.
Sep.03
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
UK HMRC Urges Public to Report Suspicious Vape Shops in Crackdown on Tax Fraud, Money Laundering and Illicit Tobacco Sales
UK HMRC Urges Public to Report Suspicious Vape Shops in Crackdown on Tax Fraud, Money Laundering and Illicit Tobacco Sales
HM Revenue & Customs is urging members of the public to report vape shops, barber shops and other high-street businesses suspected of tax fraud, money laundering or other illegal activity, with informants not required to provide personal details. HMRC plans more than 30,000 interventions in 2026-27 targeting tax fraud, organised crime and illicit activity, including the sale of illegal vapes and tobacco. The push forms part of a broader UK effort to tackle organised crime on high streets, backed by a £30 million government enforcement programme.
Regulations
Aug.17 by 2Firsts Perspectives
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11